<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ezetimibe: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ezetimibe: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ezetimibe: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12460" href="/d/html/12460.html" rel="external">see "Ezetimibe: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12909" href="/d/html/12909.html" rel="external">see "Ezetimibe: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F169566"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Zetia</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866865"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACH-Ezetimibe;</li>
<li>AG-Ezetimibe;</li>
<li>APO-Ezetimibe;</li>
<li>AURO-Ezetimibe;</li>
<li>BIO-Ezetimibe;</li>
<li>Ezetrol;</li>
<li>GLN-Ezetimibe;</li>
<li>JAMP-Ezetimibe;</li>
<li>M-Ezetimibe;</li>
<li>Mar-Ezetimibe;</li>
<li>MINT-Ezetimibe;</li>
<li>NRA-Ezetimibe;</li>
<li>PMS-Ezetimibe;</li>
<li>Priva-Ezetimibe [DSC];</li>
<li>RAN-Ezetimibe;</li>
<li>RIVA-Ezetimibe [DSC];</li>
<li>SANDOZ Ezetimibe;</li>
<li>TEVA-Ezetimibe</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F169589"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antilipemic Agent, 2-Azetidinone</li></ul></div>
<div class="block doa drugH1Div" id="F169570"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0cf1be53-8ecc-4afa-ba04-0ea66bf5b771">Atherosclerotic cardiovascular disease, primary or secondary prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Atherosclerotic cardiovascular disease, primary or secondary prevention:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>May use as an additional agent in patients who do not meet cholesterol treatment goals with dietary modification plus maximally tolerated statin therapy or as an alternative agent in patients intolerant of statins (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36031461','lexi-content-ref-30586774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36031461','lexi-content-ref-30586774'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 10 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36031461','lexi-content-ref-26039521']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36031461','lexi-content-ref-26039521'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fd41d012-a565-4b3d-8239-3e4a3f82254b">Familial hypercholesterolemia, homozygous or heterozygous</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Familial</b>
<b> hypercholesterolemia, homozygous or heterozygous:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May use as an additional agent in patients who do not meet cholesterol treatment goals with maximally tolerated statin therapy or as an alternative agent in patients intolerant of statins. Multiple lipid-lowering therapies are usually required. For homozygous familial hypercholesterolemia, treatment should be guided by an experienced lipid specialist (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36031461']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36031461'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 10 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e96f68f9-a4e0-4d4e-97d3-b568c8caac9d">Homozygous sitosterolemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Homozygous sitosterolemia: Oral:</b> 10 mg once daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991785"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Mild to severe impairment: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be dialyzed (highly protein bound): No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed (highly protein bound): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988969"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment (Child-Pugh class A): There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate to severe impairment (Child-Pugh class B or C): Use of ezetimibe not recommended.</p>
<p style="text-indent:0em;">
<b>Acute hepatotoxicity during treatment:</b> Consider discontinuing therapy if ALT or AST is persistently ≥3 times ULN.</p></div>
<div class="block dot drugH1Div" id="F56698895"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Myopathy (muscle pain, tenderness, or weakness associated with elevated creatinine kinase) and/or rhabdomyolysis: Discontinue therapy if suspected or confirmed.</p></div>
<div class="block doe drugH1Div" id="F169571"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F169583"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12909" href="/d/html/12909.html" rel="external">see "Ezetimibe: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="560908d5-ebc4-44c2-80e2-fb9e5eb5b6b8">Hyperlipidemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperlipidemia: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Children 5 to 8 years: Limited data available: Oral: 10 mg once daily; dosing based on two studies of monotherapy; a prospective trial (n=17 including six patients ≤9 years) and a retrospective review (n=36, age range: 8 to 17 years) showed significant decreases in total cholesterol and LDL-C; patients were followed up to a mean of 13.6 months, no untoward effects were noted (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Clauss.2009','lexi-content-ref-19694195']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Clauss.2009','lexi-content-ref-19694195'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥9 years and Adolescents: Oral: 10 mg once daily in combination with a statin and other LDL-C lowering therapies. Has also been shown in small pediatric trials to decrease total cholesterol and LDL-C when used as monotherapy as adjunct to dietary changes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Clauss.2009','lexi-content-ref-19694195','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Clauss.2009','lexi-content-ref-19694195','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51109802"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperlipidemia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥9 years and Adolescents: No dosage adjustments are recommended.</p></div>
<div class="block dohp drugH1Div" id="F51109803"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperlipidemia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥9 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Mild hepatic impairment: No dosage adjustments are recommended.</p>
<p style="text-indent:-2em;margin-left:6em;">Moderate to severe impairment: Use is not recommended; the effects of increased ezetimibe exposure are unknown.</p></div>
<div class="block arsc drugH1Div" id="F56268759"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Hepatic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Increased serum transaminases </b>and hepatotoxicity have been associated with ezetimibe. A higher incidence of elevated transaminases (≥3 x ULN) has been observed with concurrent use of ezetimibe with statins compared to statin monotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18173814']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18173814'])">Ref</a></span>). Acute liver injury, ranging from <b>hepatocellular</b>
<b>hepatitis</b> to <b>cholestatic</b>
<b>hepatitis</b>, has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18763297','lexi-content-ref-33644733','lexi-content-ref-17219067','lexi-content-ref-18467918','lexi-content-ref-16797241','lexi-content-ref-18752389']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18763297','lexi-content-ref-33644733','lexi-content-ref-17219067','lexi-content-ref-18467918','lexi-content-ref-16797241','lexi-content-ref-18752389'])">Ref</a></span>). <b>Autoimmune hepatitis</b>-like syndrome has also been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16797241','lexi-content-ref-16168199']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16797241','lexi-content-ref-16168199'])">Ref</a></span>). Since ezetimibe is frequently administered with other lipid-lowering agents, especially statins, it is difficult to assess the role of ezetimibe in causality of hepatotoxicity. If elevated transaminase levels do occur, they will often return to baseline with or without discontinuation of therapy. In patients with severe hepatotoxicity, resolution of symptoms usually occurs within 1 to 4 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18763297','lexi-content-ref-33644733','lexi-content-ref-17219067','lexi-content-ref-16797241','lexi-content-ref-16168199']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18763297','lexi-content-ref-33644733','lexi-content-ref-17219067','lexi-content-ref-16797241','lexi-content-ref-16168199'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related; unknown. Conjugation defect may lead to accumulation of toxic levels of ezetimibe in the liver in genetically predisposed patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16797241','lexi-content-ref-16168199']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16797241','lexi-content-ref-16168199'])">Ref</a></span>). An immune-mediated response may be implicated in cases of autoimmune hepatitis-like syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18173814','lexi-content-ref-17219067','lexi-content-ref-16168199']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18173814','lexi-content-ref-17219067','lexi-content-ref-16168199'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; ranged from 1 to 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18763297','lexi-content-ref-33644733','lexi-content-ref-17219067','lexi-content-ref-18467918','lexi-content-ref-16797241']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18763297','lexi-content-ref-33644733','lexi-content-ref-17219067','lexi-content-ref-18467918','lexi-content-ref-16797241'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of statins (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18173814','lexi-content-ref-18752389']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18173814','lexi-content-ref-18752389'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting hepatic impairment (not recommended in patients with moderate [Child-Pugh score 7 to 9] or severe [Child-Pugh score 10 to 15] hepatic impairment)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Muscle-related effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Ezetimibe, when used alone or in combination with statin therapy, has been linked to several muscle-related effects, including <b>myalgia</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADRAC.2005','lexi-content-ref-27039291']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADRAC.2005','lexi-content-ref-27039291'])">Ref</a></span>), <b>myopathy</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26600650','lexi-content-ref-15096354','lexi-content-ref-16490482','lexi-content-ref-15492351','lexi-content-ref-16485049','lexi-content-ref-17253923']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26600650','lexi-content-ref-15096354','lexi-content-ref-16490482','lexi-content-ref-15492351','lexi-content-ref-16485049','lexi-content-ref-17253923'])">Ref</a></span>), and <b>rhabdomyolysis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31943612']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31943612'])">Ref</a></span>). Creatine kinase levels often normalize within 4 weeks of discontinuation of ezetimibe (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15096354','lexi-content-ref-17253923']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15096354','lexi-content-ref-17253923'])">Ref</a></span>). Since ezetimibe is frequently co-administered with statins, which are commonly associated with muscle-related adverse effects, it is difficult to assess causality in many cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17368279']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17368279'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Unknown; impaired fatty acid oxidation may lead to ezetimibe-induced muscle related effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15492351']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15492351'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; can present hours to 4 months, with most symptoms developing within 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADRAC.2005','lexi-content-ref-26600650','lexi-content-ref-15096354']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADRAC.2005','lexi-content-ref-26600650','lexi-content-ref-15096354'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of a statin or fibrate</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting muscle disease (eg, McArdle disease) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15897216']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15897216'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Risk factors for muscle-related effects with statins (eg, older adults, hypothyroidism, kidney impairment)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F169537"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported with monotherapy in children, adolescents, and adults unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum transaminases (≥3 × ULN: monotherapy: &lt;1%; with HMG-CoA reductase inhibitors: 1%)<span class="lexi-table-link-container"> (<a aria-label="Increased Serum Transaminases table link" class="lexi-table-link" data-table-id="lexi-content-increased-serum-transaminases" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-increased-serum-transaminases')">table 1</a>)</span><span class="table-link" style="display:none;">Increased Serum Transaminases</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Increased Serum Transaminases" frame="border" id="lexi-content-increased-serum-transaminases" rules="all">
<caption style="text-align:center;">
<b>Ezetimibe: Adverse Reaction: Increased Serum Transaminases</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ezetimibe)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (HMG-CoA Reductase Inhibitors)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Monotherapy; ≥3 × ULN</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Initiated concurrently with HMG-CoA reductase inhibitors; ≥3 × ULN</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Sinusitis (3%), upper respiratory tract infection (4%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema multiforme</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, cholecystitis, cholelithiasis, nausea, pancreatitis (Ahmad 2007)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombocytopenia (Pattis 2008)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Autoimmune hepatitis (Stolk 2006), cholestatic hepatitis (Stolk 2006), hepatocellular hepatitis (Liu 2007)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Depression, dizziness, headache, paresthesia</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Increased creatine phosphokinase in blood specimen, myalgia (Nissen 2016), myopathy (Brahmachari 2015), rhabdomyolysis (Emerson 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Night blindness (Xu 2023), photophobia (Xu 2023), vision color changes (dyschromatopsia) (Xu 2023), visual field loss (Xu 2023)</p></div>
<div class="block coi drugH1Div" id="F169551"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to ezetimibe or any component of the formulation; concomitant use with a statin, fenofibrate, or other LDL-C lowering therapy when contraindications are present for such therapies.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F169535"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Systemic exposure is increased in hepatic impairment. Use is not recommended in patients with moderate or severe hepatic impairment (Child-Pugh classes B and C).</p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney impairment: No dose adjustment is necessary. In patients with severe kidney impairment (CrCl ≤30 mL/minute/1.73 m<sup>2</sup>) systemic exposure is increased ~1.5-fold.</p></div>
<div class="block foc drugH1Div" id="F169545"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zetia: 10 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg</p></div>
<div class="block geq drugH1Div" id="F169532"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F169553"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Ezetimibe Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $2.62 - $11.30</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Zetia Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $15.86</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866866"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ezetrol: 10 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg</p></div>
<div class="block adm drugH1Div" id="F169548"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral: </b>May be administered without regard to meals. May be taken at the same time as a statin or fenofibrate. Administer ≥2 hours before or ≥4 hours after bile acid sequestrants.</p></div>
<div class="block admp drugH1Div" id="F52612798"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May be taken without regard to meals; may be administered with a statin (eg, atorvastatin, simvastatin) or fenofibrate. Administer ≥2 hours before or ≥4 hours after bile acid sequestrants.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed dose: </i>Administer missed dose as soon as possible; do not administer double dose at the next scheduled dose.</p></div>
<div class="block use drugH1Div" id="F169546"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Atherosclerotic cardiovascular disease, primary or secondary prevention:</b> For treatment of primary hyperlipidemia or mixed hyperlipidemia. Use as an adjunctive therapy to diet and an HMG-CoA reductase inhibitor or as monotherapy if an HMG-CoA reductase inhibitor is not tolerated to reduce total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B, and non-high-density lipoprotein cholesterol.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Familial hypercholesterolemia, homozygous or heterozygous:</b> In combination with a high-intensity statin for the reduction of elevated total-C and LDL-C levels in patients with homozygous or heterozygous familial hypercholesterolemia.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Homozygous sitosterolemia:</b> As adjunctive therapy to diet for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolemia.</p></div>
<div class="block mst drugH1Div" id="F169597"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Ezetimibe may be confused with ezogabine</p>
<p style="text-indent:-2em;margin-left:4em;">Zetia may be confused with Zebeta, Zestril</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F9837686"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OATP1B1/1B3 (SLCO1B1/1B3)</p></div>
<div class="block dri drugH1Div" id="F169539"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Asciminib: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the absorption of Ezetimibe. Management: Administer ezetimibe at least 2 hours before or 4 hours after any bile acid sequestrant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Ezetimibe may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Ezetimibe. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Darolutamide: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eltrombopag: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fenofibrate and Derivatives: May enhance the adverse/toxic effect of Ezetimibe. Specifically, the risk of myopathy and cholelithiasis may be increased. Fenofibrate and Derivatives may increase the serum concentration of Ezetimibe.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fibric Acid Derivatives: May enhance the adverse/toxic effect of Ezetimibe. Specifically, the risk of myopathy and cholelithiasis may be increased. Fibric Acid Derivatives may increase the serum concentration of Ezetimibe.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leniolisib: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teriflunomide: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trofinetide: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors). Management: Avoid concurrent use with OATP1B1/1B3 substrates for which small changes in exposure may be associated with serious toxicities. Monitor for evidence of an altered response to any OATP1B1/1B3 substrate if used together with trofinetide.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voclosporin: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F169554"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse events were observed in some animal reproduction studies.</p>
<p style="text-indent:0em;margin-top:2em;">Outcome data following maternal use of ezetimibe during pregnancy are limited (Vuignier 2021).</p>
<p style="text-indent:0em;margin-top:2em;">If lipid-lowering therapy during pregnancy is required, it should be individualized based on the therapeutic needs of the patient, considering the lifetime risk of untreated disease, and the known risks and benefits of available therapies (CCS [Pearson 2021]).</p></div>
<div class="block brc drugH1Div" id="F20617120"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if ezetimibe is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Breastfeeding is not recommended by the manufacturer unless the potential benefits of treatment to the mother outweigh the possible risk to the breastfed infant.</p></div>
<div class="block dic drugH1Div" id="F169555"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Before initiation of therapy, patients should be placed on a standard cholesterol-lowering diet for 6 weeks and the diet should be continued during drug therapy.</p></div>
<div class="block mop drugH1Div" id="F169543"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Signs or symptoms of myopathy, CPK.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>American College of Cardiology/American Heart Association blood cholesterol guideline recommendations (ACC/AHA [Grundy 2019]):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Lipid panel (total cholesterol, HDL-C, LDL-C, triglycerides): </b>Lipid profile (fasting or nonfasting) before initiating treatment. Fasting lipid profile should be rechecked 4 to 12 weeks after starting therapy and every 3 to 12 months thereafter (AHA/ACC [Grundy 2019]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hepatic transaminase levels:</b> Baseline LFTs (reasonable); when used in combination with statin therapy, monitor LFTs when clinically indicated. When used in combination with fenofibrate, monitor LFTs and signs and symptoms of cholelithiasis.</p></div>
<div class="block pha drugH1Div" id="F169534"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits absorption of cholesterol at the brush border of the small intestine via the sterol transporter, Niemann-Pick C1-Like1 (NPC1L1). This leads to a decreased delivery of cholesterol to the liver, reduction of hepatic cholesterol stores and an increased clearance of cholesterol from the blood; decreases total C, LDL-cholesterol (LDL-C), ApoB, and triglycerides (TG) while increasing HDL-cholesterol (HDL-C).</p></div>
<div class="block phk drugH1Div" id="F169550"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Pharmacokinetic data in children and adolescents ≥10 years of age are reported to be similar to that in adult patients.</p>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Within 1 week; Maximum effect: 2 to 4 weeks.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &gt;90% to plasma proteins.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Undergoes glucuronide conjugation in the small intestine and liver; forms metabolite (active); may undergo enterohepatic recycling.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 22 hours (ezetimibe and metabolite).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: 4-12 hours (ezetimibe); 1-2 hours (active metabolite); Effects: ~2 weeks.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (78%, 69% as ezetimibe); urine (11%, 9% as metabolite).</p></div>
<div class="block phksp drugH1Div" id="F51154125"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Severe renal dysfunction (CrCl &lt;30 mL/minute/1.73 m<sup>2</sup>): AUC increased 1.5 times.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic impairment: Moderate hepatic impairment (Child-Pugh score 7 to 9): AUC increased 3 to 4 times; severe hepatic impairment (Child-Pugh 10 to 15): AUC increased 5 to 6 times.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Plasma concentrations are approximately 2-fold higher.</p>
<p style="text-indent:-2em;margin-left:2em;">Sex: Plasma concentrations for total ezetimibe were slightly higher (less than 20%) in women than in men.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F169556"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Elanix | Etimib | Etimicol | Ezechol | Ezetrol | Zetex | Zetmol</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Acarimar | Acotral | Alin | Coracil | Eszopixen | Ezetrol | Filocin | Ixacor | Nalecol | Pamelin | Trilip | Vadel | Zetia</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Ezegelan | Ezetimib +pharma | Ezetimib accord | Ezetimib actavis | Ezetimib aristo | Ezetimib genericon | Ezetimib hcs | Ezetimib hexal | Ezetimib Ratiopharm | Ezetimib sandoz | Ezetimib stada | Ezetrol</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo-ezetimibe | Blooms The Chemist Ezetimibe | Ezemichol | Ezetimibe gh | Ezetimibe Sandoz | Ezetrol | Pharmacor ezetimibe | Zient</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Cholinor | Ezeta | Ezetim</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Ezetimib ab | Ezetimibe apotex | Ezetimibe eg | Ezetimibe krka | Ezetimibe mylan | Ezetimibe Sandoz | Ezetrol</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Ezen | Ezetimibe actavis | Ezetrol</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Coledue | Ezet | Ezetimiba | Ezetrol | Posicor | Zeterina | Zetia | Zimiex</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Ezetimib axapharm | Ezetimib mepha teva | Ezetimib sandoz | Ezetimib spirig hc | Ezetimib zentiva | Ezetimibe MSD | Ezetimibe organon | Ezetrol</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Ezetrol | Eztim | Zient</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ezetrol</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Ezetimiba | Ezetimiba mk | Ezetrol | Tiazomet | Zemib | Zetia</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Adezop | Coltowan | Egitim | Ezantris | Ezen | Ezetimib apotex | Ezetimib aurovitas | Ezetimib mylan | Ezetimib stada | Ezetimib teva | Ezetimibe accord | Ezetimibe glenmark | Ezetrol | Ezoleta | Noveze | Tezzimi</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Ezetad | Ezetimib 1a pharma | Ezetimib accord | Ezetimib al | Ezetimib alkem | Ezetimib aristo | Ezetimib ascend | Ezetimib aurobindo | Ezetimib axiromed | Ezetimib basics | Ezetimib beta | Ezetimib denk | Ezetimib glenmark | Ezetimib hexal | Ezetimib micro lab | Ezetimib mylan | Ezetimib puren | Ezetimib stada | Ezetimib zentiva | Ezetimibe AbZ | Ezetimibe Heumann | Ezetimibe hexal | Ezetimibe ratiopharm | Ezetrol | Ezetrol aaha | Ezetrol aca | Ezetrol bb farma | Viemm | Zetia</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Ezetrol | Hipolipem | Lipofar | Zetia</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Ezetrol | Zient</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Ezetimibe accord | Ezetimibe elvim | Ezetrol | Ezoleta</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Choletimb | Cholguard | Cholstop | Ezetrol | Lipidnorm | Zetamibe | Zetlip</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Absorcol | Adacai | Azibe | Ezetimiba almus | Ezetimiba alter | Ezetimiba apotex | Ezetimiba aristo | Ezetimiba aurovita | Ezetimiba cinfa | Ezetimiba combix | Ezetimiba kern pharma | Ezetimiba krka | Ezetimiba mabo | Ezetimiba mylan | Ezetimiba normon | Ezetimiba pensa | Ezetimiba qualigen | Ezetimiba ranbaxy | Ezetimiba ratiopharm | Ezetimiba sandoz | Ezetimiba stada | Ezetimiba tarbis | Ezetimiba tecnigen | Ezetimiba teva | Ezetimiba viso farmaceutica | Ezetrol</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Ezetrol</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Ezetimib krka | Ezetimib medical valley | Ezetimib sandoz | Ezetimib stada | Ezetimibe accord | Ezetimibe mylan | Ezetimibe orion | Ezetimibe ratiopharm | Ezetrol</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Ezetimibe accord | Ezetimibe almus | Ezetimibe alter | Ezetimibe arrow | Ezetimibe biogaran | Ezetimibe cristers | Ezetimibe Dci | Ezetimibe eg | Ezetimibe evolugen | Ezetimibe krka | Ezetimibe MSD | Ezetimibe mylan | Ezetimibe ranbaxy | Ezetimibe Sandoz | Ezetimibe teva | Ezetimibe zentiva | Ezetimibe zydus | Ezetrol</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Ezetrol</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Cildar | Delipid | Erezel | Ezefril heremco | Ezegros | Ezetiben | Ezetimibe mylan | Ezetimibe Sandoz | Ezetrol | Mibezet | Olufsent | Quver | Zertya | Zetiraf | Zetratak s</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Ezetimibe Sandoz | Ezetrol | Lipez | Pms Ezetimibe</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Elanix | Ezetrol</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Coltowan | Ezetimib adamed | Ezetimib egis | Ezetimibe Sandoz | Ezoleta</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Ezefer | Ezetrol | Mierin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Ezetimibe apotex | Ezetimibe krka | Ezetimibe rowa | Ezetimibe teva | Ezetrol</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Ezecor | Ezetrol</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Etimibe | Ezedoc | Ezee | Ezentia | Ezetib | Ezewin | Ezibloc | Ezitrol | Ezlip | Ezta | Eztim | Ezzicad | Filet | Imbibe | Lipezet | Mibe | Zeteze | Zetica | Zetimax</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Absorcol | Corintus | Emetib | Ezelip | Ezetimibe accord | Ezetimibe alter | Ezetimibe Aristo | Ezetimibe aurobindo | Ezetimibe Doc generici | Ezetimibe eg | Ezetimibe mylan | Ezetimibe pensa | Ezetimibe Sandoz | Ezetimibe TecniGen | Ezetimibe Teva Italia | Ezetimibe zentiva | Ezetrol | Kobey | Lezimis | Mibecol | Zetia</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Ezetrol | Xitrol</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Zetia</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Ezechol | Ezentia | Ezetrol | Ezzicad</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Eazetibe | Ection | Ekibe | Elytibe | Emibe | Etev | Etib | Etimi | Ezeb | Ezeba | Ezebaera | Ezebi | Ezelive | Ezemibe | Ezenti | Ezerol | Ezesrol | Ezet | Ezeten | Ezeterol | Ezeti | Ezetib | Ezetiba | Ezetibe | Ezetim | Ezetine | Ezetol | Ezetrol | Ezetron | Ezit | Eztirol | Ezyrol | Ezytip | Gentrol | Lowterol | New easy time | Seoul ezetimibe</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Ezechol | Ezetrol | Zetex | Zetmol</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Acotral | Ezechol | Ezetimibe biogaran | Ezetral | Ezetrol | Zemil</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Ezetimib krka | Ezetimibe elvim | Ezetrol | Ezoleta</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Ezetimib Ratiopharm | Ezetimibe mylan | Ezetrol</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Ezetimibe accord | Ezetimibe elvim | Ezetrol | Ezoleta</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Zelip</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Bogaferil | Edizat | Exotib | Ezcube | Ezetimiba | Ezetrol | Kazimibe | Malugamo | Trezecol | Tromdex | Zient</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Accord ezetimibe | Ezetrol | Ezzicad | Letimble | Zeteze</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Ezetimibe accord | Ezetimibe aurobindo | Ezetimibe cf | Ezetimibe glenmark | Ezetimibe mylan | Ezetimibe Sandoz | Ezetimibe teva | Ezetrol</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Ezetimib aristo | Ezetimib krka | Ezetimib sandoz | Ezetimibe accord | Ezetimibe orion | Ezetrol</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Ezemibe | Ezetimibe Sandoz | Ezetrol</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Ezetrol | Ezzy t | Zetia</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Ezetrol | Ledipsa</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Eezit | Ezebrix | Ezetasim | Ezetrol | Ezita | Gelita | Simnex | Zemitra | Zetab</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Coltowan | Esetin | Etibax | Exebir | Ezehron | Ezen | Ezetimibe apotex | Ezetimibe aurovitas | Ezetimibe genoptim | Ezetimibe mylan | Ezetrol | Ezoleta | Ezolip | Lipegis | Mizetib | Symezet</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Zetia</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Ezetimiba | Ezetimiba alter | Ezetimiba aurovitas | Ezetimiba Azevedos | Ezetimiba bluepharma | Ezetimiba ciclum | Ezetimiba deka | Ezetimiba farmoz | Ezetimiba generis | Ezetimiba gp | Ezetimiba krka | Ezetimiba lumec | Ezetimiba mylan | Ezetimiba pharmakern | Ezetimiba sandoz | Ezetimiba tetrafarma | Ezetimiba teva | Ezetimiba zentiva | Ezetrol | Vyeve</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Colestorex | Ezetimibe dallas | Vasoflex</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Ezetrol | Letirol | Zetmol</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Cexado | Coltowan | Ezetimib accord | Ezetrol</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Ezetrol | Lipobon | Otrio</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo-ezetimibe | Ezechol | Ezetrol | Pms Ezetimibe | Zetex</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Ezetimib accord | Ezetimib actavis | Ezetimib aristo | Ezetimib krka | Ezetimib medical valley | Ezetimib sandoz | Ezetimib stada | Ezetimibe glenmark | Ezetimibe mylan | Ezetimibe zentiva | Ezetrol</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Ezetimibe Sandoz | Ezetrol | Zimiex</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Elanix | Ezetrol | Ezoleta</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Adezop | Ezantris | Ezen | Ezetimib mylan | Ezetimib stada | Ezetimib teva | Ezetimibe glenmark | Ezetimibe Sandoz | Ezetrol | Ezoleta | Lipobon</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Ezentia | Ezetimibe Sandoz | Ezetrol | Ezomib | Zetia</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Ezemib</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Ezetec | Ezetrol | Kolez</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Ezetimibe Sandoz | Ezetity | Ezetrol | Ezzicad</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Lipobon</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Coraxan | Ezet | Ezetimibe Aterimibe</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ezetrol | Zetia | Zient</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Gon sa ezeti | Vasetib | Zetamed</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Ducetim | Ezentia | Ezetimibe 10 teva | Ezetimibe Sandoz | Ezetimibe unicorn | Ezetrol | Ezorb | Mibezit | Mibitez | Nitasol | Tactus | Toleze | Trezecol</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-17458405">
<a name="17458405"></a>Ahmad I, Ruby E, Usman H, Hotiana M, Hussain M, Rahman F. Ezetimibe-induced acute pancreatitis. <i>South Med J</i>. 2007;100(4):409-410. doi:10.1097/SMJ.0b013e3180374e4b<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ezetimibe-drug-information/abstract-text/17458405/pubmed" id="17458405" target="_blank">17458405</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADRAC.2005">
<a name="ADRAC.2005"></a>Australia Adverse Drug Reactions Advisory Committee. Ezetimibe and muscle disorders. <i>Aust Adv Drug Reactions Bull.</i> 2005;24:4. <a href="https://www.tga.gov.au/sites/default/files/aadrb-0508.pdf" target="_blank">https://www.tga.gov.au/sites/default/files/aadrb-0508.pdf</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26600650">
<a name="26600650"></a>Brahmachari B, Chatterjee S. Myopathy induced by statin-ezetimibe combination: Evaluation of potential risk factors. <i>Indian J Pharmacol</i>. 2015;47(5):563-564. doi:10.4103/0253-7613.165178<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ezetimibe-drug-information/abstract-text/26600650/pubmed" id="26600650" target="_blank">26600650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26039521">
<a name="26039521"></a>Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. <i>N Engl J Med</i>. 2015;372(25):2387-2397. doi:10.1056/NEJMoa1410489<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ezetimibe-drug-information/abstract-text/26039521/pubmed" id="26039521" target="_blank">26039521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18763297">
<a name="18763297"></a>Castellote J, Ariza J, Rota R, Girbau A, Xiol X. Serious drug-induced liver disease secondary to ezetimibe. <i>World J Gastroenterol</i>. 2008;14(32):5098-5099. doi:10.3748/wjg.14.5098<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ezetimibe-drug-information/abstract-text/18763297/pubmed" id="18763297" target="_blank">18763297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Clauss.2009">
<a name="Clauss.2009"></a>Clauss S, Wall K, Kavey RW, et al. Ezetimibe treatment of pediatric patients with hypercholesterolemia. <i>J Pediatr</i>. 2009;154:869-872.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31943612">
<a name="31943612"></a>Emerson A, Gonski P. Polypharmacy induced myositis. <i>Intern Med J</i>. 2020;50(1):128-130. doi:10.1111/imj.14687<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ezetimibe-drug-information/abstract-text/31943612/pubmed" id="31943612" target="_blank">31943612</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18173814">
<a name="18173814"></a>Florentin M, Liberopoulos EN, Elisaf MS. Ezetimibe-associated adverse effects: what the clinician needs to know. <i>Int J Clin Pract</i>. 2008;62(1):88-96. doi:10.1111/j.1742-1241.2007.01592.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ezetimibe-drug-information/abstract-text/18173814/pubmed" id="18173814" target="_blank">18173814</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15096354">
<a name="15096354"></a>Fux R, Mörike K, Gundel UF, Hartmann R, Gleiter CH. Ezetimibe and statin-associated myopathy. <i>Ann Intern Med</i>. 2004;140(8):671-672. doi:10.7326/0003-4819-140-8-200404200-00034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ezetimibe-drug-information/abstract-text/15096354/pubmed" id="15096354" target="_blank">15096354</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12034651">
<a name="12034651"></a>Gagne C, Gaudet D, Bruckert E, et al. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. <i>Circulation. </i>2002;105(21):2469-2475.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ezetimibe-drug-information/abstract-text/12034651/pubmed" id="12034651" target="_blank">12034651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30586774">
<a name="30586774"></a>Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i>. 2019;139(25):e1082-e1143. doi:10.1161/CIR.0000000000000625<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ezetimibe-drug-information/abstract-text/30586774/pubmed" id="30586774" target="_blank">30586774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16750452">
<a name="16750452"></a>Gustavson LE, Schweitzer SM, Burt DA, et al. Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: A phase I, open-label, multiple-dose, three-period crossover study in healthy subjects. <i>Clin Ther.</i> 2006;28 (3):373-387.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ezetimibe-drug-information/abstract-text/16750452/pubmed" id="16750452" target="_blank">16750452</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16490482">
<a name="16490482"></a>Havranek JM, Wolfsen AR, Warnke GA, Phillips PS. Monotherapy with ezetimibe causing myopathy. <i>Am J Med</i>. 2006;119(3):285-286. doi:10.1016/j.amjmed.2005.06.051<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ezetimibe-drug-information/abstract-text/16490482/pubmed" id="16490482" target="_blank">16490482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17368279">
<a name="17368279"></a>Jacobson TA, Armani A, McKenney JM, Guyton JR. Safety considerations with gastrointestinally active lipid-lowering drugs. <i>Am J Cardiol</i>. 2007;99(6A):47C-55C. doi:10.1016/j.amjcard.2006.11.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ezetimibe-drug-information/abstract-text/17368279/pubmed" id="17368279" target="_blank">17368279</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26699442">
<a name="26699442"></a>Jacobson TA, Maki KC, Orringer CE, et al; NLA Expert Panel. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 2 [published correction appears in <i>J Clin Lipidol</i>. 2016;10(1):211]. <i>J Clin Lipidol</i>. 2015;9(6)(suppl):S1-S122.e1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ezetimibe-drug-information/abstract-text/26699442/pubmed" id="26699442" target="_blank">26699442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17368279">
<a name="17368279"></a>Jacobson TA, Marman A, McKenney JM, et al. Safety considerations with gastrointestinally active lipid-lowering drugs. <i>Am J Cardiol.</i> 2007;99(6A):47C-55C.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ezetimibe-drug-information/abstract-text/17368279/pubmed" id="17368279" target="_blank">17368279</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28437620">
<a name="28437620"></a>Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. <i>Endocr Pract</i>. 2017;23(suppl 2):1-87. doi:10.4158/EP171764.APPGL<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ezetimibe-drug-information/abstract-text/28437620/pubmed" id="28437620" target="_blank">28437620</a>]</span>
<span class="doi">10.4158/EP171764.APPGL</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33644733">
<a name="33644733"></a>Kanagalingam T, Lazarte J, Wong DKH, Hegele RA. Liver injury associated with ezetimibe monotherapy. <i>CJC Open</i>. 2020;3(2):195-197. doi:10.1016/j.cjco.2020.09.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ezetimibe-drug-information/abstract-text/33644733/pubmed" id="33644733" target="_blank">33644733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17219067">
<a name="17219067"></a>Liu Q, Tobias H, Petrovic LM. Drug-induced liver injury associated with ezetimibe therapy. <i>Dig Dis Sci</i>. 2007;52(2):602-605. doi:10.1007/s10620-006-9497-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ezetimibe-drug-information/abstract-text/17219067/pubmed" id="17219067" target="_blank">17219067</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36031461">
<a name="36031461"></a>Lloyd-Jones DM, Morris PB, Ballantyne CM, et al; Writing Committee. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee. <i>J Am Coll Cardiol</i>. 2022;80(14):1366-1418. doi:10.1016/j.jacc.2022.07.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ezetimibe-drug-information/abstract-text/36031461/pubmed" id="36031461" target="_blank">36031461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12773075">
<a name="12773075"></a>Mauro VF, Tuckerman CE. Ezetimibe for management of hypercholesterolemia. <i>Ann Pharmacother.</i> 2003;37(6):839-848.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ezetimibe-drug-information/abstract-text/12773075/pubmed" id="12773075" target="_blank">12773075</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NHLBI.2011">
<a name="NHLBI.2011"></a>National Heart, Lung, and Blood Institute. Expert panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. Clinical Practice Guidelines, 2011, National Institutes of Health. <a href="http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf%20" target="_blank">http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf </a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27039291">
<a name="27039291"></a>Nissen SE, Stroes E, Dent-Acosta RE, et al; GAUSS-3 Investigators. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: The GAUSS-3 randomized clinical trial. <i>JAMA</i>. 2016;315(15):1580-1590. doi:10.1001/jama.2016.3608<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ezetimibe-drug-information/abstract-text/27039291/pubmed" id="27039291" target="_blank">27039291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18252832">
<a name="18252832"></a>Pattis P, Wiedermann CJ. Ezetimibe-associated immune thrombocytopenia. <i>Ann Pharmacother</i>. 2008;42(3):430-433. doi:10.1345/aph.1K614<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ezetimibe-drug-information/abstract-text/18252832/pubmed" id="18252832" target="_blank">18252832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33781847">
<a name="33781847"></a>Pearson GJ, Thanassoulis G, Anderson TJ, et al. 2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. <i>Can J Cardiol.</i> 2021;37(8):1129-1150. doi:10.1016/j.cjca.2021.03.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ezetimibe-drug-information/abstract-text/33781847/pubmed" id="33781847" target="_blank">33781847</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15897216">
<a name="15897216"></a>Perez-Calvo J, Civeira-Murillo F, Cabello A. Worsening myopathy associated with ezetimibe in a patient with McArdle disease. <i>QJM</i>. 2005;98(6):461-462. doi:10.1093/qjmed/hci074<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ezetimibe-drug-information/abstract-text/15897216/pubmed" id="15897216" target="_blank">15897216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18765432">
<a name="18765432"></a>Peto R, Emberson J, Landray M, et al. Analysis of cancer data from three ezetimibe trials. <i>N Engl J Med.</i> 2008;359(13):1357-1366. Available at http://content.nejm.org/cgi/content/full/NEJMsa0806603
                     <span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ezetimibe-drug-information/abstract-text/18765432/pubmed" id="18765432" target="_blank">18765432</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15492351">
<a name="15492351"></a>Phillips PS. Ezetimibe and statin-associated myopathy. <i>Ann Intern Med</i>. 2004;141(8):649. doi:10.7326/0003-4819-141-8-200410190-00021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ezetimibe-drug-information/abstract-text/15492351/pubmed" id="15492351" target="_blank">15492351</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18467918">
<a name="18467918"></a>Ritchie SR, Orr DW, Black PN. Severe jaundice following treatment with ezetimibe. <i>Eur J Gastroenterol Hepatol</i>. 2008;20(6):572-573. doi:10.1097/MEG.0b013e3282f1752d<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ezetimibe-drug-information/abstract-text/18467918/pubmed" id="18467918" target="_blank">18467918</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18765433">
<a name="18765433"></a>Rossebo AB, Pederson TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. <i>N Engl J Med.</i> 2008;359(13):1343-1356. http://content.nejm.org/cgi/content/full/NEJMoa0804602
                     <span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ezetimibe-drug-information/abstract-text/18765433/pubmed" id="18765433" target="_blank">18765433</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16485049">
<a name="16485049"></a>Simard C, Poirier P. Ezetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. <i>Can J Cardiol</i>. 2006;22(2):141-144. doi:10.1016/s0828-282x(06)70253-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ezetimibe-drug-information/abstract-text/16485049/pubmed" id="16485049" target="_blank">16485049</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16797241">
<a name="16797241"></a>Stolk MF, Becx MC, Kuypers KC, et al. Severe hepatic side effects of ezetimibe. <i>Clin Gastroenterol Hepatol.</i> 2006;4(7):908-911.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ezetimibe-drug-information/abstract-text/16797241/pubmed" id="16797241" target="_blank">16797241</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24222016">
<a name="24222016"></a>Stone NJ, Robinson JG, Lichtenstein AH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(25 suppl 2):S1-45. doi:10.1161/01.cir.0000437738.63853.7a. Erratum in: <i>Circulation</i>. 2014;129(25 suppl 2):S46-S48. Erratum in: <i>Circulation</i>. 2015;132(25):e396.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ezetimibe-drug-information/abstract-text/24222016/pubmed" id="24222016" target="_blank">24222016</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIH.2013">
<a name="NIH.2013"></a>National Institute of Health. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III Final Report); November 2013. <a href="https://www.nhlbi.nih.gov/health-topics/all-publications-and-resources/third-report-expert-panel-detection-evaluation-and-0" target="_blank">https://www.nhlbi.nih.gov/health-topics/all-publications-and-resources/third-report-expert-panel-detection-evaluation-and-0</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12612501">
<a name="12612501"></a>Three new drugs for hyperlipidemia. <i>Med Lett Drugs Ther</i>. 2003;45(1151):17-19.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ezetimibe-drug-information/abstract-text/12612501/pubmed" id="12612501" target="_blank">12612501</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24323134">
<a name="24323134"></a>Tonelli M, Wanner C; Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. Lipid management in chronic kidney disease: synopsis of the kidney disease: Improving global outcomes 2013 clinical practice guideline. <i>Ann Intern Med</i>. 2014;160(3):182. doi: 10.7326/M13-2453.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ezetimibe-drug-information/abstract-text/24323134/pubmed" id="24323134" target="_blank">24323134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18752389">
<a name="18752389"></a>Tuteja S, Pyrsopoulos NT, Wolowich WR, et al. Simvastatin-ezetimibe-induced hepatic failure necessitating liver transplantation. <i>Pharmacotherapy</i>. 2008;28(9):1188-1193. doi:10.1592/phco.28.9.1188<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ezetimibe-drug-information/abstract-text/18752389/pubmed" id="18752389" target="_blank">18752389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-vonBergmann.2002">
<a name="vonBergmann.2002"></a>von Bergmann K, Salen G, Lutjohann D, et al. Ezetimibe effectively reduces serum plant sterols in patients with sitosterolemia (abstract). 73rd European Atherosclerosis Society Congress, 2002. Available at http://www.kenes.com/73eas/program/abstracts/405.doc
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16168199">
<a name="16168199"></a>van Heyningen C. Drug-induced acute autoimmune hepatitis during combination therapy with atorvastatin and ezetimibe. <i>Ann Clin Biochem</i>. 2005;42(Pt 5):402-304. doi:10.1258/0004563054890105<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ezetimibe-drug-information/abstract-text/16168199/pubmed" id="16168199" target="_blank">16168199</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34105316">
<a name="34105316"></a>Vuignier Y, Beaud F, Kosinski C, et al. Exposure to alirocumab during the first trimester of pregnancy: a case report. <i>Birth Defects Res.</i> 2021;113(15):1156-1160. doi:10.1002/bdr2.1930<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ezetimibe-drug-information/abstract-text/34105316/pubmed" id="34105316" target="_blank">34105316</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17253923">
<a name="17253923"></a>Weffald LA, Flach LA. Myopathy associated with atorvastatin-ezetimibe combination therapy. <i>Pharmacotherapy</i>. 2007;27(2):309-311. doi:10.1592/phco.27.2.309<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ezetimibe-drug-information/abstract-text/17253923/pubmed" id="17253923" target="_blank">17253923</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19694195">
<a name="19694195"></a>Yeste D, Chacon P, Clemente M, et al. Ezetimibe as monotherapy in the treatment of hypercholesterolemia in children and adolescents. <i>J Pediatr Endocrinol Metabl</i>. 2009;22(6):487-492.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ezetimibe-drug-information/abstract-text/19694195/pubmed" id="19694195" target="_blank">19694195</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37128259">
<a name="37128259"></a>Xu Z, Preda V, Jabbour J. Concentric reversible visual field loss, nyctalopia, and dyschromatopsia with ezetimibe therapy. <i>Case Rep Ophthalmol</i>. 2023;14(1):185-193. doi:10.1159/000530221<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ezetimibe-drug-information/abstract-text/37128259/pubmed" id="37128259" target="_blank">37128259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zetia.2021.06">
<a name="Zetia.2021.06"></a>Zetia (ezetimibe) [prescribing information]. Jersey City, NJ: Organon LLC; July 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 8790 Version 385.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
